Home › Funds › Kynam Capital Management, LP › URGN

Kynam Capital Management, LP position in URGN

UROGEN PHARMA LTD · Health Care

Kynam Capital Management, LP reported holding 2,434,207 shares of URGN (UROGEN PHARMA LTD) in its Q2 2026 13F filing — a position valued at US$89.6M, representing 4.95% of its reported portfolio and ranking #9 among its reported holdings. Kynam Capital Management, LP has disclosed URGN holdings in 5 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)2.43M sh
Reported value held$89.58M
Portfolio Weight4.95%
First reportedQ1 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Kynam Capital Management, LP's URGN position evolved

Kynam Capital Management, LP first disclosed a stake in URGN in Q1 2025 at 25,000 shares (US$276K). The position peaked in Q2 2026 at 2,434,207 shares, worth US$89.6M. Across 5 filings, Kynam Capital Management, LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,434,207 shares valued at US$89.6M — an increase of 186,814 shares quarter over quarter.. Notable position changes include a 2526% increase in Q2 2025 (shares rose 46% over the following quarter), a 57% trim in Q3 2025 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 25.00K $276.50K New
Q2 2025 656.57K $9.00M Add
Q3 2025 282.41K $6.94M Reduce
Q1 2026 2.25M $40.41M New
Q2 2026 2.43M $89.58M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 39 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Jefferies Financial Group Inc. (US$80.9M), ACORN CAPITAL ADVISORS, LLC (US$61.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has Kynam Capital Management, LP held URGN?

Kynam Capital Management, LP has disclosed URGN holdings in 5 of the last 6 reported quarters, going back to Q1 2025.

What is Kynam Capital Management, LP's current position in URGN?

As of Q2 2026, Kynam Capital Management, LP holds 2.43M shares of URGN (UROGEN PHARMA LTD), valued at $89.58M, representing 4.95% of its reported portfolio and ranking #9.

Has Kynam Capital Management, LP been buying or selling URGN?

In the latest 13F filing (Q2 2026), Kynam Capital Management, LP increased its position in URGN. The position peaked in Q2 2026 at 2.43M shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Jefferies Financial Group Inc., ACORN CAPITAL ADVISORS, LLC, among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.